References

2. Jaffe ES, Harris NL, Stein H et al. Pathology and Genetics of Tumours of Haematopoietic and Lymphoid Tissues. 2001;


56. Derenne S, Monia B, Dean NM et al. Antisense strategy shows that Mcl-1 rather than Bcl-2 or Bcl-x(L) is an essential survival protein of human myeloma cells. Blood 2002;100:194-9.


60. Quintanilla-Martinez L, Kremer M, Specht K et al. Analysis of signal transducer and activator of transcription 3 (Stat 3) pathway in multiple myeloma: Stat 3 activation and cyclin D1 dysregulation are mutually exclusive events. American Journal of Pathology 2003;162:1449-61.


65. Lacey DL, Timms E, Tan HL et al. Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation. Cell 1998;93:165-76.


References


77. Tian E. Elevated expression of WNT signaling antagonists DKK1 and FrzB by malignant plasma cells is strongly associated with lytic bone disease in myeloma. The Hematology Journal 2003;S19.


85. Rajkumar SV. *A randomised phase III trial of thalidomide plus dexamethasone versus dexamethasone in newly diagnosed multiple myeloma (E1A00): a trial coordinated by the Eastern Cooperative Oncology Group.* Proceedings of the American Society of Clinical Oncology 2004;558.


References

99. Richardson PG. A multi-center randomized phase II study to evaluate the efficacy and safety of two CC-5013 dose regimens, when used alone or in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. Blood 2002;100:104a (abstract).


147. Vellenga E, de Wolf JThM, Beentjes JAM et al. **Divergent effects of interleukin-4 (IL-4) on the granulocyte colony-stimulating factor and IL-3-supported myeloid colony formation from normal and leukemic bone marrow cells.** Blood 1990;75:633-7.
References


References

References


193. Oakervee HE, McBride NC, Hemmaway CJ. Thalidomide combined with vincristine, adriamycin and dexamethasone (T-VAD) is effective treatment for multiple myeloma and does not prejudice successful stem cell harvesting. Blood 2002;100:402A.


197. Chung F, Palmer BD, Muller GW et al. Effect of 3-fluorothalidomide and 3-methylthalidomide enantiomers on tumor necrosis factor production and antitumor responses to the antivascular agent 5,6-dimethylxanthene-4-acetic acid (DMXAA). Oncology Research 2003;14:75-82.


References


246. Okuno Y, Takahashi T, Suzuki A et al. **Establishment and characterization of four myeloma cell lines which are responsive to interleukin-6 for their growth.** Leukemia 1991;5:585-91.


267. Chesi M, Nardini E, Brents LA et al. **Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3.** Nature Genetics 1997;16:260-4.

268. Trudel S, Stewart AK, Rom E et al. **The inhibitory anti-FGFR3 antibody, PRO-001, is cytotoxic to t(4;14) multiple myeloma cells.** Blood 2006;107:4039-46.

